

Media release

DKSH enters into partnership with Luye Pharma Group in Thailand

DKSH, the leading Market Expansion Services provider with a focus on Asia, has partnered with Luye Pharma Group to sell and distribute the company's drugs used to treat symptoms of schizophrenia and bipolar disorder across medical and pharmacy channels in Thailand.

Bangkok, June 2, 2020 – DKSH Business Unit Healthcare, Asia's leading partner for healthcare companies seeking to grow their business, has signed a new partnership with Luye Pharma Group, a leading pharmaceutical company dedicated to R&D, manufacturing and sale of innovative medications. Under the full agency agreement, DKSH will hold marketing authorization for Luye Pharma in Thailand. DKSH will manage marketing and sales as well as logistics for Luye Pharma's treatments for schizophrenia and bipolar disorder. DKSH will also help the company drive sales growth through its capabilities and strengths in the medical and pharmacy channels.

Luye Pharma has established R&D centers in China, the U.S. and Europe, with a robust pipeline of more than 40 drug candidates in China and more than ten drug candidates overseas. Key products covering four therapeutic areas – oncology, cardiovascular, metabolism and central nervous system – with central nervous system and oncology considered core strategic areas. Luye Pharma and DKSH have also launched the "We Care About Mental Health" initiative to raise awareness of mental health issues and support patients, physicians and health systems in overcoming the unmet needs, especially during this challenging time of the Covid-19 pandemic.

The collaboration between Luye Pharma and DKSH is to ensure more accessibility of medicines to patients in Thailand. As part of the "We Care About Mental Health" initiative, the two companies are committed to organizing a series of online and offline lectures hosted by experts in the field of mental health, helping to educate the public and further raise awareness of matters related to mental illness.

"Mental health is a serious, global public health challenge that requires a sustained and united response from us all," said Andy Siow, APAC Regional Director of Luye Pharma International. "By partnering with DKSH in Thailand, we are confident that the 'We Care About Mental Health' initiative will help to increase understanding and awareness of mental health issues. It will also provide insights on the available treatment options and emphasize how important it is for sufferers to seek treatment."

John Clare, Vice President, Healthcare, DKSH Thailand and Indochina, said: "We are proud to partner with a company, which, like us, believes in improving access to healthcare products for all. We provide the best possible services to our clients as well as healthcare professionals, so that they, in turn, can take care of patients. With a broad reach across various distribution channels, from pharmacies, to hospitals and clinics, we are committed to driving expansion for Luye Pharma in Thailand."

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the US and Europe, with a robust pipeline of over 40 drug candidates in China and more than ten drug candidates in other international markets. Along with a number of new drugs and formulations in the central nervous system and oncology therapeutic areas currently under study in the US, Europe and Japan, Luye Pharma has reached high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems, as well as actively making strategic developments in the fields of biological antibodies, cell therapies and gene therapies, among others.

Luye Pharma is developing a global supply chain of eight manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With

Delivering growth – in Asia and beyond.

more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets. For more information, visit www.luye.cn/luye_en.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps companies to grow across the Business Units Healthcare, Consumer Goods, Performance Materials and Technology. The service portfolio covers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 36 markets with 33,350 specialists, generating net sales of CHF 11.6 billion in 2019. With its Swiss heritage, DKSH has been deeply rooted in Asia Pacific since 1865. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 8,220 specialists, the Business Unit generated net sales of CHF 6.0 billion in 2019.

For further information, please contact:**DKSH Business Unit Healthcare**

Krittiya Wongtavavimarn
Group Communications, Healthcare
+66 2 220 9070
krittiya.w@dksh.com